Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | Director | June 23, 2025 | June 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date June 23, 2025 · Filed June 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2035-06-22 | Direct | 16,000 |
Reported balance
After 2025-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-23 · Grant · Acquired 16,000 · Balance 16,000 F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2025 Filed Jun 23, 2025 17:21 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-25-089089 · ownership.xml · derivative · entry 1 Brennan Christine · CIK 0002016488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-22 F1 · derivative.exercise_date: The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 16:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 26,438 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038698 · ownership.xml · derivative · entry 1 Brennan Christine · CIK 0002016488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,438 Underlying: Common Stock · 26,438 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.